Completion of Genetype Risk Assessment Portfolio Acquisition
Filed with ASX · · 1 page · English
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- RHY Acquires Genetype Genetic Risk Assessment Business
- Pause in Trading
- Market Update - All End of CY24 Milestones Attained
- Strong Demand in Share Placement to Raise $3.5 million
- Receipt of Research & Development Tax Incentive
Later from Rhythm Biosciences
- About the Genetype Acquisition
- Quarterly Activities Report and Appendix 4C - Dec24
- Genetype Commercial Integration Completion
- RHY Investor Webinar
- RHY Genetype Commercial Sales
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences